Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Never miss an Options trading signal: Unusual Options Activity and Options Screeners with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Coherus Oncology Inc (CHRS)

Coherus Oncology Inc (CHRS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 193,394
  • Shares Outstanding, K 120,871
  • Annual Sales, $ 266,960 K
  • Annual Income, $ 28,510 K
  • EBIT $ -178 M
  • EBITDA $ -172 M
  • 60-Month Beta 0.96
  • Price/Sales 0.67
  • Price/Cash Flow 5.69
  • Price/Book 2.20

Options Overview Details

View History
  • Implied Volatility 121.20% (-58.64%)
  • Historical Volatility 66.53%
  • IV Percentile 10%
  • IV Rank 5.43%
  • IV High 670.52% on 11/17/25
  • IV Low 89.67% on 08/13/25
  • Expected Move (DTE 32) 0.4505 (28.16%)
  • Put/Call Vol Ratio 0.05
  • Today's Volume 231
  • Volume Avg (30-Day) 307
  • Put/Call OI Ratio 0.04
  • Today's Open Interest 20,416
  • Open Int (30-Day) 19,796
  • Expected Range 1.1495 to 2.0505

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 6 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/25
See More
  • Average Estimate -0.36
  • Number of Estimates 2
  • High Estimate -0.36
  • Low Estimate -0.36
  • Prior Year -0.44
  • Growth Rate Est. (year over year) +18.18%

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.2700 +25.98%
on 12/29/25
1.7750 -9.86%
on 01/09/26
+0.2100 (+15.11%)
since 12/16/25
3-Month
1.0900 +46.79%
on 11/21/25
1.8200 -12.09%
on 10/21/25
-0.1100 (-6.43%)
since 10/16/25
52-Week
0.7100 +125.35%
on 06/23/25
1.8900 -15.34%
on 10/09/25
+0.1800 (+12.68%)
since 01/16/25

Most Recent Stories

More News
Targeted Precision: Rare Disease Assets Attract Record Regulatory Momentum

Issued on behalf of Oncolytics Biotech Inc. VANCOUVER – Baystreet.ca News Commentary – Genomics-driven cancer diagnostics are accelerating market growth, with the genomics in cancer care market...

ONCY : 1.0100 (+3.80%)
IDYA : 35.84 (-0.61%)
ZLAB : 18.58 (-1.28%)
CHRS : 1.6000 (-3.61%)
HALO : 71.21 (-0.85%)
Coherus Management to Present at the 44th Annual J.P. Morgan Healthcare Conference

REDWOOD CITY, Calif., Jan. 06, 2026 (GLOBE NEWSWIRE) -- Coherus Oncology, Inc. (NASDAQ: CHRS) today announced that senior management will present at the 44th Annual J.P. Morgan Healthcare Conference...

CHRS : 1.6000 (-3.61%)
Coherus Oncology Announces Publication in Molecular Cancer Therapeutics Highlighting the Strong Pharmacology of Investigational CCR8 Antibody Tagmokitug (CHS-114)

-Coherus Oncology formally introduces non-proprietary name:  tagmokitug- -Publication shows picomolar affinity for CCR8 with no off-target binding and proof-of- mechanism in preclinical and clinical...

CHRS : 1.6000 (-3.61%)
Coherus Announces Six-Year JUPITER-02 Follow-up Results Showing LOQTORZI® plus Chemotherapy Nearly Doubles Median Overall Survival in Nasopharyngeal Carcinoma

REDWOOD CITY, Calif., Dec. 08, 2025 (GLOBE NEWSWIRE) -- Coherus Oncology, Inc. (NASDAQ: CHRS) today announced compelling six-year overall survival (OS) follow-up results from the Phase 3 JUPITER-02 trial...

CHRS : 1.6000 (-3.61%)
Coherus Oncology Presents at SITC Clinical Multiomic Biomarker Data for CHS-114, a Highly Selective anti-CCR8 Cytolytic Antibody

– CHS-114 demonstrated robust and selective depletion of CCR8+ Tregs as well as favorable immune remodeling in tumor tissue from head and neck squamous cell carcinoma (HNSCC) patients – – CHS-114...

CHRS : 1.6000 (-3.61%)
Coherus Oncology: Q3 Earnings Snapshot

Coherus Oncology: Q3 Earnings Snapshot

CHRS : 1.6000 (-3.61%)
Coherus Oncology Reports Third Quarter 2025 Financial Results and Provides Business Update

– CHS-114, a highly selective Treg depleter, clinical program expanded to include colorectal cancer – – Q3 2025 ending cash, cash equivalents and marketable securities of $191.7 million –...

CHRS : 1.6000 (-3.61%)
Arvind Sood joins Coherus Oncology as Chief Strategy and Corporate Affairs Officer

–  Responsible for Corporate Development, Investor Relations, Government Affairs – REDWOOD CITY, Calif., Nov. 06, 2025 (GLOBE NEWSWIRE) -- Coherus Oncology, Inc. (Nasdaq: CHRS), today announced...

CHRS : 1.6000 (-3.61%)
Coherus Oncology to Report Third Quarter 2025 Financial Results on November 6, 2025

REDWOOD CITY, Calif., Oct. 30, 2025 (GLOBE NEWSWIRE) -- Coherus Oncology, Inc . (Nasdaq: CHRS), today announced that its third quarter 2025 financial results will be released after market close on...

CHRS : 1.6000 (-3.61%)
Coherus Oncology Announces Poster Presentation at the 40th Annual Meeting of the Society for Immunotherapy of Cancer (SITC)

REDWOOD CITY, Calif., Oct. 03, 2025 (GLOBE NEWSWIRE) -- Coherus Oncology, Inc. (NASDAQ: CHRS), today announced an upcoming poster presentation at the 40th Annual Meeting of the Society for Immunotherapy...

CHRS : 1.6000 (-3.61%)

Business Summary

Coherus is a fully integrated commercial-stage innovative oncology company. Coherus, formerly known as Coherus BioSciences Inc., is based in REDWOOD CITY, Calif.

See More

Key Turning Points

3rd Resistance Point 1.7300
2nd Resistance Point 1.7000
1st Resistance Point 1.6500
Last Price 1.6000
1st Support Level 1.5700
2nd Support Level 1.5400
3rd Support Level 1.4900

See More

52-Week High 1.8900
Last Price 1.6000
Fibonacci 61.8% 1.4392
Fibonacci 50% 1.3000
Fibonacci 38.2% 1.1608
52-Week Low 0.7100

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar